In this –this episode of the Onco’Zine Brief, Peter Hofland is talking with Dr. Matthias Bucerius. Dr. Bucerius is Vice President and General Manager at MilliporeSigma. He is responsible for Contract Development and Manufacturing Organsation (CDMO) business of the company, leading a fully integrated global team with Manufacturing Operations, Commercial, Marketing & Strategy, Technology & Innovation organizations. The company is helping its clients in developing and manufacturing a variety of products, including antibody-drug conjugates. Antibody-drug conjugates or ADCs are targeted therapies that have opened new ways in targeting diseases like cancer and hematological malignancies. What is unique about ADCs is that they leverage the specific targetability benefits offered by antibodies and combine that with the high potency of small-molecule drugs. This combination makes these agents uniquely targetable therapies. And unlike traditional chemotherapy, these ADCs target tumors by delivering the attached payload to destroy cancer cells while sparing the healthy or normal cells, thereby potentially reducing negative side effects for patients.
